Bispecific antibody conjugates in therapeutics

  • Cao Y
  • Lam L
  • 54

    Readers

    Mendeley users who have this article in their library.
  • 67

    Citations

    Citations of this article.

Abstract

Bispecific monoclonal antibodies have drawn considerable attention from the research community due to their unique structure against two different antigens. The two-arm structure of bsMAb allows researchers to place a therapeutic agent on one arm while allowing the other to specifically target the disease site. The therapeutic agent can be a drug, toxin, enzyme, DNA, radionuclide, etc. Furthermore, bsMAb may redirect the cytotoxicity of immune effector cells towards the diseased cells or induce a systemic immune response against the target. BsMAb holds great promise for numerous therapeutic needs in the light of: (1) recent breakthroughs in recombinant DNA technology, (2) the increased number of identified disease targets as the result of the completion of human genomic map project, and (3) a better understanding of the mechanism of human immune system. This review focuses on therapeutic applications and production of bsMAb while providing the up-to-date clinical trial information. © 2002 Elsevier Science B.V. All rights reserved.

Author-supplied keywords

  • ADEPT
  • Bispecific monoclonal antibody
  • BsMAb
  • Gene therapy
  • Immunotherapy
  • Radioimmunotherapy
  • Vaccine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Ying Cao

  • Laura Lam

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free